Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  American Journal of Kidney Diseases

• Publication date

  2001-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/AJKD.2001.26839PMID 11532682
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients.

  2000cited by this paper
• The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin.

  1999cited by this paper
• ect of losartan on haemoglobin concentration in renal transplant recipients — a retrospective analysis

  1998cited by this paper
• High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients.

  1998cited by this paper
• Is plasma Ac-SDKP level a reliable marker of chronic angiotensin-converting enzyme inhibition in hypertensive patients?

  1998cited by this paper
• High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients.

  1997cited by this paper
• Production and consumption of the tetrapeptide AcSDKP, a negative regulator of hematopoietic stem cells, by hematopoietic microenvironmental cells.

  1997cited by this paper
• High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.

  1997cited by this paper
• Angiotensin II stimulates proliferation of normal early erythroid progenitors.

  1997cited by this paper
• Effects of the angiotensin‐converting enzyme inhibitor enalapril on blood haematopoietic progenitors and Acetyl‐N‐Ser‐Asp‐Lys‐Pro concentrations

  1997cited by this paper
• Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients.

  1996cited by this paper
• The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.

  1996cited by this paper
• Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.

  1996cited by this paper
• Is erythropoietin a survival factor for red blood cells?

  1996cited by this paper
• The tetrapeptide AcSDKP, a negative regulator of cell cycle entry, inhibits the proliferation of human and chicken lymphocytes.

  1996cited by this paper
• Erythropoietin in chronic renal failure.

  1996cited by this paper
• The Hemoregulatory Peptide N-Acetyl-Ser-Asp-Lys-Pro Is a Natural and Specific Substrate of the N-terminal Active Site of Human Angiotensin-converting Enzyme (*)

  1995cited by this paper
• Inhibitory peptides in hematopoiesis.

  1995cited by this paper
• Peripheral blood mononuclear cells from patients with chronic renal failure release factors which suppress erythropoietin secretion in vitro.

  1994cited by this paper
• Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors.

  1993cited by this paper
• The beneficial effect of enalapril on erythrocytosis after renal transplantation.

  1993cited by this paper
• Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia.

  1993cited by this paper
• Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline.

  1993cited by this paper
• Does captopril decrease the effect of human recombinant erythropoietin in haemodialysis patients?

  1993cited by this paper
• Enalapril-associated anemia in renal transplant recipients treated for hypertension.

  1991cited by this paper
• Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay.

  1990cited by this paper
• Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP.

  1990cited by this paper
• The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.

  1990cited by this paper
• Do polyamines play a role in the pathogenesis of the anemia of end-stage renal disease?

  1989cited by this paper
• The physiological role of the endogenous colony forming units-spleen (CFU-S) inhibitor acetyl-N-Ser-Asp-Lys-Pro (AcSDKP).

  1989cited by this paper
• The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin.

  1989cited by this paper
• Worsening of anemia induced by long-term use of captopril in hemodialysis patients.

  1984cited by this paper
• Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure.

  1984cited by this paper
• Effect of angiotensin infusion on extrarenal erythropoietin production.

  1982cited by this paper
• Enalapril (MK-421) and the white cell count and haematocrit.

  1982cited by this paper
• Effect of parathyroid hormone on erythropoiesis.

  1981cited by this paper
• Interrelation of the renin system and erythropoietin in rats.

  1980cited by this paper
• Inhibition of CFU entry into cycle by a bone marrow extract.

  1977cited by this paper

• Thymosin beta 4: An Emerging Therapeutic Candidate for Kidney Diseases.

  2026cites this paper
• UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease

  2025cites this paper
• Elements for economic evaluation on online Hemodiafiltration (ol-HDF) versus standard Haemodialysis to treat patients with End-Stage Renal Disease (ESRD)

  2024cites this paper
• N-acetyl-seryl-aspartyl-lysyl-proline: A new potential serum biomarker of rheumatoid arthritis

  2021cites this paper
• Haematological Indicators of Response to Erythropoietin Therapy in Chronic Renal Failure Patients on Haemodialysis: Impact of Angiotensin-Converting Enzyme rs4343 Gene Polymorphism

  2021cites this paper
• Pleiotropic effect of erythropoiesis-stimulating agents on circulating endothelial progenitor cells in dialysis patients

  2021cites this paper
• LONG-TERM STUDY OF ERYTHROPOIETIN, LOSARTAN, AND COMBINATION IN STREPT- OZOTOCIN-INDUCED DIABETIC RATS

  2020cites this paper
• Hematologic Complications of Chronic Kidney Disease—Anemia and Platelet Disorders

  2020cites this paper
• Anemia in Chronic Kidney Disease

  2019cites this paper
• Thymosin-β4: A key modifier of renal disease

  2018cites this paper
• EFFECT OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ON HEMOGLOBIN LEVELS AMONG PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE: A RANDOMIZED CONTROL TRIAL

  2018cites this paper
• The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases.

  2018cites this paper
• Residual renal function in chronic dialysis is not associated with reduced erythropoietin-stimulating agent dose requirements: a cross-sectional study

  2017cites this paper
• Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease

  2017cites this paper
• AcSDKP is down-regulated in anaemia induced by Trypanosoma brucei infection in mice

  2017cites this paper
• THE INFLUENCE OF ACE INHIBITORS TREATMENT ON ANEMIA PARAMETERS IN PATIENTS ON MAINTENANCE HEMODIALYSIS

  2017cites this paper
• ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage

  2016cites this paper
• Clinical Implications of Plasma N-acetyl-seryl-aspartyl-lysyl-proline Level in Stable Kidney Transplant Recipients.

  2016cites this paper
• The role of thymosin-β4 in kidney disease

  2015cites this paper
• Resistance of dialyzed patients to erythropoietin

  2015cites this paper
• Hematologic Complications of Chronic Kidney Disease

  2015cites this paper
• Effect of angiotensin-converting enzyme gene insertion/deletion polymorphism and angiotensin-converting enzyme inhibition on erythropoiesis in patients on haemodialysis

  2015cites this paper
• N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain.

  2015cites this paper
• Parvovirus B19 (B19) and cytomegalovirus (CMV) infections and anti-erythropoietin (anti-EPO) antibodies in patients on dialysis hyporesponsive to erythropoietin therapy.

  2014cites this paper
• Significant decrease in plasma N-acetyl-seryl-aspartyl-lysyl-proline level in patients with end stage renal disease after kidney transplantation.

  2014cites this paper
• Darbepoetin Alfa Increases Plasma N-acetyl seryl-aspartyl-lysyl-proline Level in Kidney Transplant Recipient: A Case Report

  2014influential citation
• Management of Anemia on Hemodialysis

  2013cites this paper
• The influence of vitamin E bonded haemodialysis membranes on erythropoiesis stimulating agent requirements, oxidative stress, inflammation, haemostasis and outcomes

  2013cites this paper
• Techniques and Kinetics of Hemodiafiltration

  2013cites this paper
• On-line solid-phase extraction LC-MS/MS for the determination of Ac-SDKP peptide in human plasma from hemodialysis patients.

  2012cites this paper
• Management of Renal Anemia in Children with Chronic Kidney Disease

  2012cites this paper
• Establishment and clinical application of a highly sensitive enzyme immunoassay for determination of N‐acetyl‐seryl‐aspartyl‐lysyl‐proline

  2012cites this paper
• Hematologic Aspects of Kidney Disease

  2012cites this paper
• Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease.

  2011cites this paper
• Renal dysfunction and anaemia in patients with heart failure – "The Cardio-Renal Anaemia Syndrome" (CRAS)

  2011cites this paper
• Renal dysfunction and anemia in patients with heart failure — the cardio-renal anemia syn- drome

  2011cites this paper
• Quantification of N-acetyl-seryl-aspartyl-lysyl-proline in hemodialysis patients administered angiotensin-converting enzyme inhibitors by stable isotope dilution liquid chromatography-tandem mass spectrometry.

  2011cites this paper
• Renal Association Clinical Practice Guideline on Anaemia of Chronic Kidney Disease

  2011cites this paper
• Renal dysfunction and anemia in patients with heart failure — the cardio-renal anemia syndrome

  2011cites this paper
• Risk factors of post renal transplant anaemia among Sudanese patients, a study in three renal transplant centres

  2011influential citation
• CHAPTER 79 – Anemia in Chronic Kidney Disease

  2010cites this paper
• Managing anemia in patients with chronic heart failure: what do we know?

  2010cites this paper
• Management of Anemia and Iron Deficiency in Heart Failure

  2010cites this paper
• Iron and anemia in human biology: a review of mechanisms

  2008cites this paper
• [Anemia as complication of chronic heart failure: prevalence, treatment, prognosis].

  2008cites this paper
• The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.

  2008cites this paper
• Erythropoietin stimulating agents in the management of anemia of chronic kidney disease

  2008cites this paper
• [Drug treatment of hypertension in hemodialysed patients].

  2007cites this paper
• Traitement pharmacologique de l’HTA en hémodialyse

  2007cites this paper
• L'anemia nel trapiantato di rene

  2007cites this paper
• Controversies in renal anemia management

  2006cites this paper
• L’Ac-SDKP : une clé pour comprendre certains effets des inhibiteurs de l’enzyme de conversion ?

  2006cites this paper
• [Ac-SDKP, a marker of the angiotensin-converting enzyme activity?].

  2006cites this paper
• KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.

  2006cites this paper
• On-Line Filtration Therapies: Emerging Horizons

  2006cites this paper
• Management of hypertension in hemodialysis patients

  2006cites this paper
• Reviews: Uremic Toxins: A New Focus on an Old Subject

  2005cites this paper
• Levels of Hematopoiesis Inhibitor N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure

  2005cites this paper
• Chronic kidney disease in the general population.

  2005cites this paper
• Drug dosing in chronic kidney disease.

  2005cites this paper
• Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis

  2005cites this paper
• Renin-angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance.

  2005cites this paper
• Anemia and erythropoietin in heart failure.

  2005cites this paper
• N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice.

  2005cites this paper
• Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization.

  2004cites this paper
• HYPERTENSION IN HEMODIALYSIS PATIENTS: Drug Therapy for Hypertension in Hemodialysis Patients

  2004cites this paper
• Efficacy of once-weekly epoetin alfa.

  2004cites this paper
• Management of anemia in patients with chronic kidney disease

  2004cites this paper
• Angiotensin II receptor type 1 expression in erythroid progenitors: Implications for the pathogenesis of postrenal transplant erythrocytosis.

  2004cites this paper
• Management of renal anemia

  2004cites this paper
• Biology of erythropoietin

  2003cites this paper
• The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.

  2003cites this paper
• On-line hemodiafiltration: technique and efficiency.

  2003cites this paper
• The thymosins. Prothymosin alpha, parathymosin, and beta-thymosins: structure and function.

  2003cites this paper
• CKD Series: Evaluation and Treatment of Anemia in Chronic Kidney Disease

  2003cites this paper
• [Progression of renal insufficiency in the pre-end-stage renal disease setting].

  2003cites this paper
• Non-erythropoietin-based anaemia management in chronic kidney disease.

  2002cites this paper
• Angiotensin-converting enzyme inhibitors and anemia in chronic kidney disease: a complex interaction.

  2002cites this paper
• The tetrapeptide N-acetyl-seryl-aspartyl-lysylproline and angiotensin-converting enzyme

  2002cites this paper
• Gender differences in responsiveness to erythropoietin.

  2002cites this paper
• Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia?

  2002cites this paper
• Do ACE inhibitors limit response to EPO and should EPO be continued in patients with sepsis or fever

  2002cites this paper
• Gender differences in responsiveness to erythropoietin: In Reply

  2002cites this paper
• Review: The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease

  2002cites this paper
• Angiotensin-converting enzyme inhibitors and anemia in chronic kidney disease: A complex interaction

  2002cites this paper
• Ace inhibitors and erythropoietin responsiveness.

  2001cites this paper
• Vascular Health and Risk Management Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Managing Anemia in Patients with Chronic Heart Failure: What Do We Know?

  year unknowncites this paper
• Management of Hypertension in the End-Stage Renal Disease Patient

  year unknowncites this paper